Low frequency of type-I and type-II aberrations in myeloid leukemia of Down syndrome, underscoring the unique entity of this disease

We recently published in this journal an overview of the currently known genetic events required for the development of pediatric acute myeloid leukemia (AML).[1][1] These aberrations can be subdivided into type-I aberrations that result in uncontrolled proliferation, and type-II aberrations that

[1]  R. Pieters,et al.  Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model , 2012, Leukemia.

[2]  M. Heuser,et al.  Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML–BFM and DCOG study groups , 2011, Leukemia.

[3]  R. Pieters,et al.  Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia , 2011, Haematologica.

[4]  R. Pieters,et al.  NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. , 2011, Blood.

[5]  M. Suarez‐Almazor,et al.  Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Julia Kuhn,et al.  WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Pieters,et al.  No prognostic impact of the WT1 gene single nucleotide polymorphism rs16754 in pediatric acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Pieters,et al.  Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. , 2010, European journal of cancer.

[9]  M. Shago,et al.  Functional differences between myeloid leukemia-initiating and transient leukemia cells in Down's syndrome , 2010, Leukemia.

[10]  R. Pieters,et al.  Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. , 2009, Blood.

[11]  L. Malcovati,et al.  Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome , 2009, Haematologica.

[12]  P Bader,et al.  Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study , 2009, Leukemia.

[13]  R. Pieters,et al.  Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. , 2008, Blood.

[14]  H. Hasle,et al.  WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder. , 2006, Leukemia research.

[15]  J. Goodwin,et al.  Comorbid disease and cancer: the need for more relevant conceptual models in health services research. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Armstrong,et al.  Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. , 2005, Blood.

[17]  Edward L Spitznagel,et al.  Prognostic importance of comorbidity in a hospital-based cancer registry. , 2004, JAMA.

[18]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[19]  H. Hasle.  Pattern of malignant disorders in individuals with Down's syndrome. , 2001, The Lancet. Oncology.

[20]  R. Pieters,et al.  University of Groningen Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia Hollink, , 2011 .

[21]  R. Pieters,et al.  Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML , 2009, Leukemia.

[22]  A. Zipursky,et al.  Origins of leukaemia in children with Down syndrome , 2005, Nature Reviews Cancer.

[23]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.